NCT02323646View on ClinicalTrials.gov

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 12, 2015

Primary Completion Date

April 6, 2017

Study Completion Date

April 6, 2017

Conditions
Uterine Fibroids
Interventions
DRUG

Placebo

Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

DRUG

Telapristone Acetate

Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

Trial Locations (8)

27612

Raleigh

30328

Sandy Springs

33316

Fort Lauderdale

48604

Saginaw

70001

Metairie

77030

Houston

77054

Houston

23235-4759

Richmond

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT02323646 - Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | Biotech Hunter | Biotech Hunter